A Pilot Study to Evaluate the Efficacy and Safety of Treatment with Botulinum Toxin in Patients with Recalcitrant and Persistent Erythematotelangiectatic Rosacea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: There are few pharmacologic options to reduce erythema and flushing in patients with recalcitrant erythematotelangiectatic rosacea (ETR). We previously reported two cases of refractory flushing and erythema of rosacea that were successfully treated with intradermal botulinum toxin injection, and additional research is needed to prove the efficacy and safety of this treatment. Objective: To report the efficacy and safety of botulinum toxin injection as an aid in persistent erythema of rosacea patients. Methods: A total of 20 Korean patients with recalcitrant ETR were enrolled to receive treatment by injection of botulinum toxin. Patients received one treatment of intradermal botulinum toxin injection and were assessed 1, 2, 4, and 8 weeks after treatment. The severity of erythema and telangiectasia was investigated by a non-treating physician, and the Erythema Index (EI) was assessed by mexameter at each visit. Patient satisfaction and any adverse events were also assessed at each visit. Results: 17 patients completed all follow-up visits and were included in the analysis. Intradermal injection of botulinum toxin significantly reduced erythema severity and EI in ETR patients. Patients reported a satisfaction score of 2.94±0.56 at 8 weeks after treatment. Except for three patients who discontinued the study early due to inconvenience of facial muscle paralysis, 17 patients participating in the final analysis did not report side effects except injection pain at the time of the procedure. Conclusion: Intradermal injection of botulinum toxin can be used as an effective and relatively safe adjuvant agent for recalcitrant and persistent erythema of ETR patients.
Abstract
Background: There are few pharmacologic options to reduce erythema and flushing in patients with recalcitrant erythematotelangiectatic rosacea (ETR). We previously reported two cases of refractory flushing and erythema of rosacea that were successfully treated with intradermal botulinum toxin injection, and additional research is needed to prove the efficacy and safety of this treatment. Objective: To report the efficacy and safety of botulinum toxin injection as an aid in persistent erythema of rosacea patients. Methods: A total of 20 Korean patients with recalcitrant ETR were enrolled to receive treatment by injection of botulinum toxin. Patients received one treatment of intradermal botulinum toxin injection and were assessed 1, 2, 4, and 8 weeks after treatment. The severity of erythema and telangiectasia was investigated by a non-treating physician, and the Erythema Index (EI) was assessed by mexameter at each visit. Patient satisfaction and any adverse events were also assessed at each visit. Results: 17 patients completed all follow-up visits and were included in the analysis. Intradermal injection of botulinum toxin significantly reduced erythema severity and EI in ETR patients. Patients reported a satisfaction score of 2.94±0.56 at 8 weeks after treatment. Except for three patients who discontinued the study early due to inconvenience of facial muscle paralysis, 17 patients participating in the final analysis did not report side effects except injection pain at the time of the procedure. Conclusion: Intradermal injection of botulinum toxin can be used as an effective and relatively safe adjuvant agent for recalcitrant and persistent erythema of ETR patients.
참고문헌 (25)
- Schwab VD, "Neurovascular and neuroimmune aspects in the pathophysiology of rosacea", J Investig Dermatol Symp Proc, 15, pp.53~62 (2011)
- Dayan SH, "A new treatment regimen for rosacea: onabotulinumtoxinA", J Drugs Dermatol, 11, pp.e76~e79 (2012)
- Bloom BS, "Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea", Dermatol Surg, 41(Suppl 1), pp.S9~S16 (2015)
- Shah AR, "Use of intradermal botulinum toxin to reduce sebum production and facial pore size", J Drugs Dermatol, 7, pp.847~850 (2008)
- Oh YJ, "A split-face study using botulinum toxin type B to decrease facial erythema index", J Cosmet Laser Ther, 13, pp.243~248 (2011)
- Welch MJ, "Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins", Toxicon, 38, pp.245~258 (2000)
- Durham PL, "Regulation of calcitonin generelated peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy", Headache, 44, pp.35~42 (2004)
- Apostolidis A, "Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity", J Urol, 174, pp.977~982 (2005)
- Gessert CE, "Measuring the severity of rosacea:a review", Int J Dermatol, 42, pp.444~448 (2003)
- Park KY, "Botulinum toxin for the treatment of refractory erythema and flushing of rosacea", Dermatology, 230, pp.299~301 (2015)
- Kellogg DL Jr, "Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission", Circ Res, 77, pp.1222~1228 (1995)
- Kellogg DL Jr, "Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans", J Appl Physiol, 113, pp.1512~1518 (2012)
- Steinhoff M, "New insights into rosacea pathophysiology: a review of recent findings", J Am Acad Dermatol, 69(6 Suppl 1), pp.S15~S26 (2013)
- Steinhoff M, "Clinical, cellular, and molecular aspects in the pathophysiology of rosacea", J Investig Dermatol Symp Proc, 15, pp.2~11 (2011)
- Drummond PD, "Endothelial and axon reflex vasodilatation to acetylcholine in rosacea-affected skin", Arch Dermatol Res, 304, pp.133~137 (2012)
- Krämer HH, "Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin", J Neurol, 250, pp.188~193 (2003)
- Tugnoli V, "Botulinum toxin type A reduces capsaicinevoked pain and neurogenic vasodilatation in human skin", Pain, 130, pp.76~83 (2007)
- Seeliger S, "Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo", Am J Pathol, 177, pp.2563~2575 (2010)
- Goswami C, "TRPV1 acts as a synaptic protein and regulates vesicle recycling", J Cell Sci, 123, pp.2045~2057 (2010)
- Sulk M, "Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea", J Invest Dermatol, 132, pp.1253~1262 (2012)
- Wang TT, "Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression", J Immunol, 173, pp.2909~2912 (2004)
- Meng J, "Activation of TRPV1 mediates calcitonin generelated peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential", J Neurosci, 29, pp.4981~4992 (2009)
- Shimizu T, "Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A", Neurobiol Dis, 48, pp.367~378 (2012)
- Li X, "Structural and functional interactions between transient receptor potential vanilloid subfamily 1 and botulinum neurotoxin serotype A", PLos One, 11, pp.e0143024~ (2016)
- Eshghi G, "Botulinum toxin A in treatment of facial flushing", Acta Med Iran, 54, pp.454~457 (2016)